[go: up one dir, main page]
More Web Proxy on the site http://driver.im/ Skip to main content

Advertisement

Springer Nature Link
Log in

Methamphetamine Psychosis: Epidemiology and Management

  • Therapy in Practice
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Psychotic symptoms and syndromes are frequently experienced among individuals who use methamphetamine, with recent estimates of up to approximately 40 % of users affected. Although transient in a large proportion of users, acute symptoms can include agitation, violence, and delusions, and may require management in an inpatient psychiatric or other crisis intervention setting. In a subset of individuals, psychosis can recur and persist and may be difficult to distinguish from a primary psychotic disorder such as schizophrenia. Differential diagnosis of primary vs. substance-induced psychotic disorders among methamphetamine users is challenging; nevertheless, with careful assessment of the temporal relationship of symptoms to methamphetamine use, aided by state-of-the art psychodiagnostic assessment instruments and use of objective indicators of recent substance use (i.e., urine toxicology assays), coupled with collateral clinical data gathered from the family or others close to the individual, diagnostic accuracy can be optimized and the individual can be appropriately matched to a plan of treatment. The pharmacological treatment of acute methamphetamine-induced psychosis may include the use of antipsychotic medications as well as benzodiazepines, although symptoms may resolve without pharmacological treatment if the user is able to achieve a period of abstinence from methamphetamine. Importantly, psychosocial treatment for methamphetamine dependence has a strong evidence base and is the optimal first-line treatment approach to reducing rates of psychosis among individuals who use methamphetamines. Prevention of methamphetamine relapse is the most direct means of preventing recurrence of psychotic symptoms and syndromes. Long-term management of individuals presenting with recurrent and persistent psychosis, even in the absence of methamphetamine use, may include both behavioral treatment to prevent resumption of methamphetamine use and pharmacological treatment targeting psychotic symptoms. In addition, treatment of co-occurring psychiatric disorders including depression and anxiety is important as a means of preventing relapse to methamphetamine use, which is often triggered by associated symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
£29.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Substance Abuse and Mental Health Services Administration (SAMHSA), 2013a. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Substance Abuse and Mental Health Services Administration, Rockville, MD.

  2. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2013. Vienna: United Nations; 2013.

    Google Scholar 

  3. Courtney KE, Ray LA. Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug Alcohol Depend. 2014;143C:11–21.

    Article  Google Scholar 

  4. Lambert D, Gale JA, Hartley D. Substance abuse by youth and young adults in rural America. J Rural Health. 2008;24:221–8.

    Article  PubMed  Google Scholar 

  5. SAMHSA [Substance Abuse and Mental Health Services Administration], Office of Applied Studies. Treatment Episode Data Set (TEDS) 1998–2008, National Admissions to Substance Abuse Treatment Services, Drugs and Alcohol Services Information System Series: S-50, HHS Publication No. (SMA) 09–4471, Rockville, MD; 2009.

  6. Shoptaw S, Peck J, Reback FJ, Rotheram-Fuller E. Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment. J Psychoactive Drugs. 2003;35(Suppl 1):161–8.

    Article  PubMed  Google Scholar 

  7. Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, Iguch M. Methamphetamine Treatment Project: psychiatric symptoms in methamphetamine users. Am J Addict. 2004;13:181–90.

    Article  PubMed  Google Scholar 

  8. McKetin R, McLaren L, Lubman DI, Hides J. The prevalence of psychotic symptoms among methamphetamine users. Addiction. 2006;101:1473–8.

    Article  PubMed  Google Scholar 

  9. McKetin R, Lubman DI, Najman JM, Dawe S, Butterworth P, Baker AL. Does methamphetamine use increase violent behaviour? Evidence from a prospective longitudinal study. Addiction. 2014;109(5):798–806.

    Article  PubMed  Google Scholar 

  10. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson RA. Clinical course and outcomes of methamphetamine-dependent adults with psychosis. J Subst Abuse Treat. 2008;35:445–50.

    Article  PubMed  Google Scholar 

  11. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson RA. Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug Alcohol Rev. 2010;29:12–20.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Chen CK, Lin SK, Sham PC, Ball D, Loh EW, Hsiao CC, Chiang YL, Ree SC, Lee CH, Murray RM. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med. 2003;33:1407–14.

    Article  CAS  PubMed  Google Scholar 

  13. Batki SL, Harris DS. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesias. Am J Addict. 2004;13:461–70.

    Article  PubMed  Google Scholar 

  14. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 1999;35:S93–100.

    Article  PubMed  Google Scholar 

  15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.

    Google Scholar 

  16. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Geneva: Diagnostic Criteria For Research; 1992.

    Google Scholar 

  17. Schuckit MA. Comorbidity between substance use disorders and psychiatric conditions. Addiction. 2006;101(Suppl 1):76–88.

    Article  PubMed  Google Scholar 

  18. Grelotti DJ, Kanayama G, Pope HG. Remission of persistent methamphetamine induced psychosis after electroconvulsie therapy: presentation of a case and review of the literature. Am J Psychiatry. 2010;167:17–23.

    Article  PubMed  Google Scholar 

  19. Bramness JG, Gundersen ØH, Guterstam J, Rognli EB, Konstenius M, Løberg EM, Medhus S, Tanum L, Franck J. Amphetamine-induced psychosis: a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry. 2012;12:221.

    Article  PubMed Central  PubMed  Google Scholar 

  20. American Psychiatric Association. American Psychiatric Association practice guidelines for the treatment of psychiatric disorders: compendium 2006. http://psychiatryonline.org/guidelines.aspx. Accessed 14 April 2014

  21. Caton CLM, Drake RE, Hasin DS, Domingues B, Shrout PE, Samet S, Schanzer B. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Arch Gen Psychiatry. 2005;52:137–45.

    Article  Google Scholar 

  22. Caton CL, Samet S, Hasin DS. When acute-stage psychosis and substance use co-occur: differentiating substance-induced and primary psychotic disorders. J Psychiatr Pract. 2000;6(5):256–66.

    Article  CAS  PubMed  Google Scholar 

  23. Olivera AA, Kiefer M, Manley NK. Tardive dyskinesia in psychiatric patients with substance abuse disorders. Am J Drug Alcohol Abuse. 1990;16:57–66.

    Article  CAS  PubMed  Google Scholar 

  24. Brown ME, Anton RF, Malcolm R, Ballenger JC. Alcohol detoxification and withdrawal seizures: clinical support for a kindling hypothesis. Biol Psychiatry. 1988;23:507–14.

    Article  CAS  PubMed  Google Scholar 

  25. McKetin R, Lubman DI, Baker AL, Dawe S, Ali RL. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiatry. 2013;70(3):319–24.

    Article  PubMed  Google Scholar 

  26. Connell PH. Amphetamine psychosis. Maudsley Monograph No. 5, London: Oxford University Press; 1958.

  27. Bell DS. Comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry. 1965;3:701.

    Article  Google Scholar 

  28. Griffith JD, Cavanaugh JH, Oates JA. Psychosis induced by the administration of d-amphetamine to human volunteers. In Efron DH, editor. Psychomimetic drugs: proceedings of a workshop organised by the Pharmacology Section, Psychopharmacology Research Branch, National Institute of Mental Health, held at the University of California, Irvine, Januray 25, 1969. New York: Raven Press; 1970.

  29. Jönsson LE, Sjöström K. A rating scale for evaluation for the clinical course and symptomatology in amphetamine psychosis. Br J Psychiatry. 1970;117:661–5.

    Article  PubMed  Google Scholar 

  30. Bell DA. The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry. 1973;29(1):35–40.

    Article  CAS  PubMed  Google Scholar 

  31. Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis: preliminary observations. Biol Psychiatry. 1970;2:95–107.

    CAS  PubMed  Google Scholar 

  32. Angrist B, Sathananthan G, Wilk S, Gershon S. Amphetamine psychosis: behavioural and biochemical aspects. J Psychiatric Res. 1974;11:13.

    Article  CAS  Google Scholar 

  33. Volkow ND. NIDA research report: methamphetamine abuse and addiction. Washington: National Institute on Drug Abuse; 2006.

    Google Scholar 

  34. Harris D, Batki SL. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict. 2000;9(1):28–37.

    Article  CAS  PubMed  Google Scholar 

  35. Lineberry TW, Bostwick JM. Methamphetamine abuse: a perfect storm of complications. Mayo Clin Proc. 2006;81(1):77–84.

    Article  PubMed  Google Scholar 

  36. Wada K, Fukui S. Relationship between years of methamphetamine use and symptoms of methamphetamine psychosis. Jpn J Alcohol Stud Drug Depend. 1990;25(3):143–58.

    CAS  Google Scholar 

  37. Wada K, Fukui S. Residual symptoms in methamphetamine psychosis. J Mental Health. 1991;37:161–8.

    Google Scholar 

  38. Sato M. Acute exacerbation of methamphetamine psychosis and lasting dopaminergic supersensitivity: a clinical survey. Psychopharmacol Bull. 1986;22(3):751–6.

    CAS  PubMed  Google Scholar 

  39. Segal DS, Kuczenski R. An escalating dose “binge” model of amphetamine psychosis: behavioral and neurochemical characteristics. J Neurosci. 1997;17(7):2551–66.

    CAS  PubMed  Google Scholar 

  40. Sato M, Chen CC, Akiyama K, Otsuki S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry. 1983;18(4):429–40.

    CAS  PubMed  Google Scholar 

  41. McKetin R, Hickey K, Devlin K, Lawrence K. The risk of psychotic symptoms associated with recreational methamphetamine use. Drug Alcohol Rev. 2010;29(4):358–63.

    Article  PubMed  Google Scholar 

  42. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl). 1987;91(4):415–33.

    Article  CAS  Google Scholar 

  43. Tsuang MT, Simpson JC, Kronfol Z. Subtypes of drug abuse with psychosis: demographic characteristics, clinical features, and family history. Arch Gen Psychiatry. 1982;39(2):141–7.

    Article  CAS  PubMed  Google Scholar 

  44. Grant KM, LeVan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, Carlo G, Bevins RA. Methamphetamine-associated psychosis. J Neuroimmune Pharmacol. 2012;7(1):113–39.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Sulaiman AH, Said MA, Habil MH, Rashid R, Siddiq A, Guan NC, Midin M, Nik Jaafar NR, Sidi H, Das S. The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia. Compr Psychiatry. 2014;55(Suppl 1):S89–94.

    Article  PubMed  Google Scholar 

  46. Vincent N, Schoobridge J, Ask A, Allsop S, Ali R. Physical and mental health problems in amphetamine users from metropolitan Adelaide, Australia. Drug Alcohol Rev. 1998;17(2):187–95.

    Article  CAS  PubMed  Google Scholar 

  47. Chen CK, Lin SK, Sham PC, Ball D, Loh EW, Murray RM. Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Genet B Neuropsychiatr Genet. 2005;136:87–91.

    Article  Google Scholar 

  48. Salo R, Nordahl TE, Leamon MH, Natsuaki Y, Moore CD, Waters C, Carter CS. Preliminary evidence of behavioral predictors of recurrent drug-induced psychosis in methamphetamine abuse. Psychiatry Res. 2008;157:273–7.

    Article  CAS  PubMed  Google Scholar 

  49. Matsumoto T, Karmijo A, Miyakawa T, Endo K, Yabana T, Kishimoto H, Okudaira K, Iseki E, Sakai T, Kosaka D. Methamphetamine in Japan: the consequences of methamphetamine abuse as a function of route of administration. Addiction. 2002;97:809–17.

    Article  PubMed  Google Scholar 

  50. Cantor-Graae E, Nordstrom LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schiz Res. 2001;48(1):69–82.

    Article  CAS  Google Scholar 

  51. Ringen PA, Melle I, Birkenaes AB, Engh JA, et al. Illicit drug use in patients with psychotic disorders compared with that in the general population: a cross-sectional study. Acta Psychiatr Scand. 2008;117(2):133–8.

    Article  CAS  PubMed  Google Scholar 

  52. Davis J, Schlemmer RF. The amphetamine psychosis. In: Caldwell J, editor. Amphetamines and related stimulants: chemical, biological, clinical, and sociological aspects. Boca Raton, FL: CRC Press; 1980. p. 161–73.

    Google Scholar 

  53. Ujike H, Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann NY Acad Sci. 2004;1025:279–87.

    Article  CAS  PubMed  Google Scholar 

  54. Akiyama K. Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence. Ann N Y Acad Sci. 2006;1074:125–34.

    Article  CAS  PubMed  Google Scholar 

  55. Akiyama K, Saito A, Shimoda K. Chronic methamphetamine psychosis after long-term abstinence in Japanese incarcerated patients. Am J Addict. 2011;20(3):240–9.

    Article  PubMed  Google Scholar 

  56. Kittirattanapaiboon P, Mahatnirunkul S, Booncharoen H, Thummawomg P, Dumrongchai U, Chutha W. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug Alcohol Rev. 2010;29(4):456–61.

    PubMed  Google Scholar 

  57. Iwanami A, Sugiyama A, Kuroki N, Toda S, Kato N, Nakatani Y, Horita N, Kaneko T. Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan: a preliminary report. Acta Psychiatrica Scandinavica. 1994;89(6):428–32.

    Article  CAS  PubMed  Google Scholar 

  58. Sato M. A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. In Kalivas PW, Samson HH, editors. The neurobiology of drug and alcohol addiction. Ann NY Acad Sci. 1992;654:160–70.

  59. Nakatani Y, Yoshizawa F, Yamada H, Iwanami A, Sakaguchi M, Katoh N. Methamphetamine psychosis in Japan: a survey. Br J Addiction. 1989;84(12):1548–9.

    Article  CAS  Google Scholar 

  60. Tomiyama G. Chronic schizophrenia-like states in methamphetamine psychosis. Jpn J Psychiatry Neurol. 1990;44(3):531–9.

    CAS  PubMed  Google Scholar 

  61. Yui K, Goto K, Ikemoto S, Nishijima K, Yoshino T, Ishiguro T. Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis. Drug Alcohol Depend. 2001;64:133–42.

    Article  CAS  PubMed  Google Scholar 

  62. Wright J. Mania following sleep deprivation. Br J Psychiatry. 1993;163:679–80.

    Article  CAS  PubMed  Google Scholar 

  63. Yui K, Goto K, Ikemoto S, Ishiguro T. Stress induced spontaneous recurrence of methamphetamine psychosis: the relation between stressful experiences and sensitivity to stress. Drug Alcohol Depend. 2000;58:67–75.

    Article  CAS  PubMed  Google Scholar 

  64. Shaner A, Roberts LJ, Eckman TA, et al. Sources of diagnostic uncertainty for chronically psychotic cocaine abusers. Psychiatr Serv. 1998;49:684–90.

    CAS  PubMed  Google Scholar 

  65. Medhus S, Mordal J, Holm B, Mørland J, Bramness JG. A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wards. Psychiatry Res. 2013;206(1):17–21.

    Article  PubMed  Google Scholar 

  66. Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry. 1996;153:1195–201.

    CAS  PubMed  Google Scholar 

  67. Robins LN, Helzer JE, Croughau J, Ratcliff KS. The National Institute of Mental Health Diagnostic Interview Schedule: its history, characteristics, and validity. Arch Gen Psychiatry. 1981;38:381–9.

    Article  CAS  PubMed  Google Scholar 

  68. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA, et al. The Composite International Diagnostic Interview: an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry. 1988;45(12):1069–77.

    Article  CAS  PubMed  Google Scholar 

  69. First MB, Spitzer RL, Williams JEW, et al. Structured Clinical Interview for DSM-IV-Clinician Version (SCID-CV) (User’s guide and interview). Washington, DC: American Psychiatric Press; 1997.

    Google Scholar 

  70. Samet S, Nunes EV, Hasin D. Diagnosis comorbidity: concepts, criteria, and methods. Acta Neuropsychiatrica. 2004;16:9–18.

    Article  Google Scholar 

  71. Bacon A, Granholm E, Withers N. Substance-induced psychosis. Semin Clin Neuropsychiatry. 1998;3:70–9.

    PubMed  Google Scholar 

  72. Cohen SI. Overdiagnosis of schizophrenia: role of alcohol and drug misuse. Lancet. 1995;346:1541–2.

    Article  CAS  PubMed  Google Scholar 

  73. Misra L, Kofoed L. Risperidone treatment of methamphetamine psychosis. Am J Psychiatry. 1997;154(8):1170.

    CAS  PubMed  Google Scholar 

  74. Misra LK, Kofoed L, Oesterheld JR, Richards GA. Olanzapine treatment of methamphetamine psychosis. J Clin Psychopharmacol. 2000;23(3):393–4.

    Article  Google Scholar 

  75. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res. 1999;35(1):51–68.

    Article  CAS  PubMed  Google Scholar 

  76. Espelin DE, Done AK. Amphetamine poisoning: effectiveness of chlorpromazine. N Engl J Med. 1968;278(25):1361–5.

    Article  CAS  PubMed  Google Scholar 

  77. Shoptaw S, Kao U, Ling W. Treatment for amphetamine psychosis. Cochrane Database Syst Rev;1:CD003026. New York: Wiley; 2009b.

  78. Leelahanaj T, Kongsakon R, Netrakom P. A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thai. 2005;88(Suppl 3):S43–52.

    PubMed  Google Scholar 

  79. Verachai V, Rukngan W, Chawanakrasaesin K, Nilaban S, Suwanmajo S, Thanateerabunjong R, Kaewkungwal J, Kalayasiri R. Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine. Psychopharmacology (Berl). 2014;231(16):3099–108.

    Article  CAS  Google Scholar 

  80. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26(2):441–9.

    Article  CAS  PubMed  Google Scholar 

  81. Noordsy DL, O’Keefe C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. J Clin Psychiatry. 1999;60(Suppl 19):47–51.

    PubMed  Google Scholar 

  82. Noordsy DL, O’Keefe C, Mueser KT, Xie H. Six-month outcomes for patients who switched to olanzapine treatment. Psychiatr Serv. 2001;52(4):501–7.

    Article  CAS  PubMed  Google Scholar 

  83. Hatzipetros T, Raudensky JG, Soghomonian JJ, Yamamoto BK. Haloperidol treatment after high-dose methamphetamine administration is excitotoxic to GABA cells in the substantia nigra pars reticulata. J Neurosci. 2007;27(22):5895–902.

    Article  CAS  PubMed  Google Scholar 

  84. Granado N, Ares-Santos S, Oliva I, O’Shea E, Martin ED, Colado MI, et al. Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol Dis. 2011;42(3):391–403.

    Article  CAS  PubMed  Google Scholar 

  85. Hall HV, McPherson SB, Yudko E. Methamphetamine use: clinical and forensic aspects. 2nd ed. New York: CRC Press; 2009.

    Google Scholar 

  86. Ling W, Mooney L, Rawson RA. Amphetamine-type stimulants. In McCrady BS, Epstein EE, editors. Addictions: a comprehensive guidebook. 2nd ed., Chapter 8. New York: Oxford University Press; 2013.

  87. Patel NC, Crismon ML, Hoagwood K, Jensen PS. Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. J Child Adolesc Psychopharmacol. 2005;15(2):270–84 Review.

    Article  PubMed  Google Scholar 

  88. McConville BJ, Sorter MT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry. 2004;65 Suppl 6:20–29.

  89. Drug & Alcohol Services South Australia. Guidelines for the medical management of patients with methamphetamine induced psychosis. 2006. http://www.vaada.org.au/wp-content/uploads/2013/10/Psychosis_guidelines.pdf. Accessed 14 April 2014

  90. Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, Galloway GP, Herrell J, Huber A, McCann MJ, Obert J, Pennell S, Reiber C, Vandersloot D, Zweben J, and the Methamphetamine Treatment Project Corporate Authors. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004;99:708–717.

  91. Rawson RA. Methamphetamine: new knowledge, new treatments. Center City, MN: Hazelden; 2006.

    Google Scholar 

  92. Elkashef A, Rawson R, Anderson A, Li SH, Holmes T, Smith E, Chiang N, Kahn R, Vocci F, Ling W, Pearce VJ, McCann M, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Weis D. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacol. 2008;33(5):1162–70.

    Article  CAS  Google Scholar 

  93. Burns AM, Erickson DH, Brenner CA. Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review. Psychiatr Serv. 2014. doi:10.1176/appi.ps.201300213. (Epub ahead of print).

  94. Roll JM, Chudzynski J, Cameron JM, Howell DN, McPherson S. Duration effects in contingency management treatment of methamphetamine disorders. Addict Behav. 2013;38(9):2455–62.

    Article  PubMed Central  PubMed  Google Scholar 

  95. Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Mooney LJ, Rawson R. Methamphetamine Treatment Project Corporate Authors depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nervous Ment Dis. 2009;197(4):225–31.

    Article  Google Scholar 

  96. Jayaram-Lindström N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J. et al. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology. 2008;33(8):1856–1863.

  97. Colfax GN, Santos GM, Das M, Santos DM, Matheson T, Gasper J, Shoptaw S, Vittinghoff E. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011;68(11):1168–75.

    Article  PubMed Central  PubMed  Google Scholar 

  98. Tiihonen J, Kuoppasalmi K, Föhr J, Tuomola P, Kuikanmäki O, Vorma H, Sokero P, Haukka J, Meririnne E. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry. 2007;164:160–2.

    Article  PubMed  Google Scholar 

Download references

Disclosures

Neither Suzette Glasner-Edwards nor Larissa Mooney has any conflict of interest. No sources of funding were used to assist in the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Integrated Substance Abuse Programs, David Geffen School of Medicine at UCLA, Semel Institute for Neuroscience and Human Behavior, 1640 S. Sepulveda Blvd., Suite 120, Los Angeles, CA, 90025, USA

    Suzette Glasner-Edwards & Larissa J. Mooney

Authors
  1. Suzette Glasner-Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Larissa J. Mooney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suzette Glasner-Edwards.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Glasner-Edwards, S., Mooney, L.J. Methamphetamine Psychosis: Epidemiology and Management. CNS Drugs 28, 1115–1126 (2014). https://doi.org/10.1007/s40263-014-0209-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-014-0209-8

Keywords

Search

Navigation